Skip to main content

OSE Seminar by Dr. Stefan Posse on Biomedical Imaging Research in Human Cancer

Departmental News

 Dr. Stefan Posse   seminar image

Posted: February 4, 2018

Date:  Wednesday, February 07, 2018
Time: 11:00 AM to Noon
Location: CHTM, Room 101

Map to CHTM:
Parking passes are available at the receptionist desk.

Abstract: Functional connectomics using resting state functional MRI is a rapidly expanding task-free approach for mapping brain functional networks, which is expected to have significant clinical applications in presurgical mapping of patients with brain lesions. Our laboratory is developing novel ultra-high-speed imaging technology to map signal fluctuations in human brain at frequencies beyond 1 Hz to characterize signal sources and to improve functional brain imaging in clinical applications. Clinical examples combing multiple imaging technologies to map functional and metabolic abnormalities in patients with brain tumors, epilepsy and vascular malformations will be presented.

The second part of the talk will describe the development of high-speed metabolic imaging to monitor treatment response in patients with breast cancer. The long-term goals are to utilize this technology as an early predictor of treatment failure in women undergoing pre-operative systemic therapy for their breast cancer and to develop an improved screening protocol for high-risk patients.


Biography Prof. Posse’s laboratory develops novel diagnostic MRI methods for characterizing human brain function and physiology, which includes ultra-high-speed real-­time functional MRI and spectroscopic MR imaging. Goals include biophysics research in MR signal sources, technology development and clinical applications aimed at improving individualized treatment strategies and prognosis based upon patient tailored imaging. Prof. Posse is a professor in the Department of Neurology, and Physics and Astronomy. He is a member of the UNM Cancer Center and has affiliations with the U. Washington and Copenhagen University in Denmark.